Examining the Impact of ASXL1 Mutations in Newly Diagnosed CML-CP

ASXL1 is the most frequently mutated gene in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP), detected in approximately 7% to 14% of cases. Because ASXL1 mutations in CML-CP are associated with lower molecular response rates, higher risk of ABL1 kinase domain mutation acquisition, and worse event-free and failure-free survival, studies examining combination strategies and novel agents are needed to offset the mutations’ negative effects and link to myeloid disorders.